Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-23
pubmed:abstractText
Influenza vaccine strains have been traditionally developed by annual reassortment between vaccine donor strain and the epidemic virulent strains. The classical method requires screening and genotyping of the vaccine strain among various reassortant viruses, which are usually laborious and time-consuming. Here we developed an efficient reverse genetic system to generate the 6:2 reassortant vaccine virus from cDNAs derived from the influenza RNAs. Thus, cDNAs of the two RNAs coding for surface antigens, haemagglutinin and neuraminidase from the epidemic virus and the 6 internal genes from the donor strain were transfected into cells and the infectious viruses of 6:2 defined RNA ratio were rescued. X-31 virus (a high- growth virus in embryonated eggs) and its cold-adapted strain X-31 ca were judiciously chosen as donor strains for the generation of inactivated vaccine and live-attenuated vaccine, respectively. The growth properties of these recombinant viruses in embryonated chicken eggs and MDCK cell were indistinguishable as compared to those generated by classical reassortment process. Based on the reverse genetic system, we generated 6+2 reassortant avian influenza vaccine strains corresponding to the A/Chicken/Korea/ MS96 (H9N2) and A/Indonesia/5/2005 (H5N1). The results would serve as technical platform for the generation of both injectable inactivated vaccine and the nasal spray live attenuated vaccine for the prevention of influenza epidemics and pandemics.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-10430945, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-10489954, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-10662626, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-11315644, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-11348696, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-11779380, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-12163268, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-13755924, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-14643124, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-14723616, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-15660212, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-16343703, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-16434109, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-16968127, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-17492465, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-17919786, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-19423869, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-5309489, http://linkedlifedata.com/resource/pubmed/commentcorrection/20054235-9240694
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1226-3613
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
116-21
pubmed:dateRevised
2010-9-27
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Reverse genetic platform for inactivated and live-attenuated influenza vaccine.
pubmed:affiliation
Department of Biotechnology, College of Bioscience and Biotechnology, Translation Research Center for Protein Function Control, Yonsei University, Seoul 120-749, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't